First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

by Enriqueta Felip, Helena Linardou, Fabrice Barlesi, Michele Maio, Luis Paz-Ares, Jonathan W Goldman, Karim Vermaelen, Osvaldo Arén Frontera, Erika Rijavec, Kevin Jao, Clarisse Audigier-valette, Han Chang, David R Spigel, Neal E Ready, Tudor-Eliade Ciuleanu, María Rosario García Campelo, Stéphanie Bordenave, Laszlo Urban, Jean-Sébastien Aucoin, Cristina Zannori, Alessandra Curioni Fontecedro, Amparo Sánchez-Gastaldo, Oscar Juan-Vidal, Elena Poddubskaya, Samreen Ahmed, Sunney Li, Joseph Fiore, Angelic Acevedo
Published 2023-02-01

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a random...

by Howard Gurney, Thomas Powles, Asim Amin, Bohuslav Melichar, Camillo Porta, David F McDermott, Toni K Choueiri, Marc-Oliver Grimm, Bernard Escudier, Elizabeth R Plimack, Brian I Rini, Hans J Hammers, Saby George, Robert J Motzer, Alain Ravaud, Osvaldo Arén Frontera, Frede Donskov, Philippe Barthélémy, Victoria Neiman, Pamela Salman, Christian K Kollmannsberger, Scott S Tykodi, Raya Leibowitz-Amit, Poul F Geertsen, Yoshihiko Tomita, M Brent McHenry, Shruti Shally Saggi, Nizar M Tannir
Published 2020-07-01